ASTS
AST SpaceMobile, Inc.
ASTS offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
CTSH
Cognizant Technology Solutions Corporation
CTSH has the edge over ASTS overall, supported by lower modeled downside and stronger valuation.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CTSH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
CTSH's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
CTSH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $63.75 | — |
| Current | 12x | $63.75 | — |
| Cheap | 14x | $75.47 | +18% |
| Fair | 17x | $92.95 | +46% |
| Expensive | 23x | $128 | +100% |
Historical ranges are pointers, not guarantees.
CTSH's PE is in its cheap range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
CTSH Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Moderate | |
| High |
Analysts expect CTSH's earnings to grow and its profitability to improve, with its revenue holding steady.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
CTSH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.16 | +12% |
| Q3 2026 | $5.49 | +27% |
| Q2 2026 | $4.66 | -5.3% |
| Q1 2026 | $4.61 | -2.9% |
| Q4 2025 | $4.56 | +1.1% |
| Q3 2025 | $4.31 | -4.9% |
| Q2 2025 | $4.92 | +12% |
| Q1 2025 | $4.75 | +14% |
| Q4 2024 | $4.51 | +7.1% |
CTSH has the edge over ASTS on earnings quality, reporting a profit while its opponent remains loss making.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS's revenue has grown year over year for 11 quarters in a row: $42M last quarter, up 187% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
CTSH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.7B | +4.6% |
| Q2 2026 | $5.5B | +4.5% |
| Q1 2026 | $5.4B | +5.8% |
| Q4 2025 | $5.3B | +4.9% |
| Q3 2025 | $5.4B | +7.4% |
| Q2 2025 | $5.2B | +8.1% |
| Q1 2025 | $5.1B | +7.5% |
| Q4 2024 | $5.1B | +6.8% |
CTSH's revenue has grown year over year for nine quarters in a row: $5.7B last quarter, up 4.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | -0.6 points |
| Q2 2026 | 16% | +0.4 points |
| Q1 2026 | 16% | -1.1 points |
| Q4 2025 | 16% | +1.2 points |
| Q3 2025 | 16% | +1.4 points |
| Q2 2025 | 16% | +1 points |
| Q1 2025 | 17% | +2.1 points |
| Q4 2024 | 15% | -0.4 points |
CTSH has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
CTSH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $925M | -20% |
| Q2 2026 | $459M | +39% |
| Q1 2026 | $198M | -39% |
| Q4 2025 | $781M | -6.7% |
| Q3 2025 | $1.2B | +47% |
| Q2 2025 | $331M | +81% |
| Q1 2025 | $323M | +1919% |
| Q4 2024 | $837M | +27% |
CTSH has the edge over ASTS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has 300M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
CTSH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.4% | -16M shares |
| 1 year | -7.6% | -37M shares |
| 3 years | -11% | -55M shares |
| 5 years | -14% | -76M shares |
| Available history | -20% | -110M shares |
CTSH has the edge over ASTS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $270M |
| Q2 2026 | $1.2B |
| Q1 2026 | $444M |
| Q4 2025 | $338M |
| Q3 2025 | $463M |
| Q2 2025 | $368M |
| Q1 2025 | $209M |
| Q4 2024 | $154M |
CTSH spent $2.2B buying back its own shares over the past year, up 86% from the year before.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CTSH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.0x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | -0.2x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
CTSH's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
CTSH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.9 | Neutral |
| Stochastic | 57.3 | Neutral |
CTSH's weekly RSI is 55 (neutral) and its Stochastic is 57 (neutral).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
CTSH PE vs Technology Sector
| Metric | CTSH | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 28x | 58% below |
| PE % | 3 | 35 | 32 pts below |
CTSH is trading at 12x earnings, a 58% discount to the Technology sector's median of 28x.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has fallen below most of its moving averages, though it's still 2.8% above its 200-week average.
CTSH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $63.2 | 1% above |
| 20 week MA | $58.0 | 9.9% above |
| 50 week MA | $62.4 | 2.1% above |
| 100 week MA | $69.0 | 7.6% below |
| 200 week MA | $69.5 | 8.3% below |
CTSH has the edge over ASTS on trend strength, trading above more of its moving averages.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
CTSH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.2 | $81.1 | +30% |
| 2021 | $81.1 | $86.3 | +6.4% |
| 2022 | $86.3 | $56.0 | -35% |
| 2023 | $56.0 | $75.5 | +35% |
| 2024 | $75.5 | $79.2 | +4.9% |
| 2025 | $79.2 | $85.6 | +8% |
| 2026 YTD | $85.6 | $63.8 | -25% |
CTSH has the edge over ASTS on returns for 2026, with the stronger performance.